Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial

Gastroenterology

Volumn 137, Issue 6, 2009, Pages 1986-1994

  Shiffman, Mitchell L ^a   Morishima, Chihiro ^b   Dienstag, Jules L ^c   Lindsay, Karen L ^d   Hoefs, John C ^e   Lee, William M ^f   Wright, Elizabeth C ^g   Naishadham, Deepa ^h   Everson, Gregory T ⁱ   Lok, Anna S ^j   Di Bisceglie, Adrian M ^k   Bonkovsky, Herbert L ^l   Ghany, Marc G ^g  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h NEW ENGLAND RESEARCH INSTITUTES   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 70849104810     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.08.067     Document Type: Article

References (27)

1. Fried M.W., Shiffman M.L., Reddy K.R., et al. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Eng J Med 347 (2002) 975-982
2. Manns M.P., McHutchinson J.G., Gordon S.C., et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
3. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997) 463-472
4. Veldt B.J., Heathcote E.J., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007) 677-684
5. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
6. Shiffman M.L., Vargus H.E., and Everson G.T. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 9 (2003) 1129-1144
7. Everson G.T., Balart L., Lee S.S., et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 27 (2008) 542-551
8. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
9. Shiffman M.L., Hofmann C.M., Thompson E.B., et al. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology 26 (1997) 780-785
10. Nishiguchi S., Shiomi S., Nakatani S., et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357 (2001) 196-197
11. Imazeki F., Yokosuka O., Fukai K., et al. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 38 (2003) 493-502
12. Shiffman M.L., Hofmann C.M., Contos M.J., et al. A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders. Gastroenterology 117 (1999) 1164-1172
13. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25 (2004) 472-492
14. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429-2441
15. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
16. Morishima C., Morgan T.R., Everhart J.E., et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 44 (2006) 360-367
17. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
18. Afdhal N.H., Levine R., Brown R., et al. Colchicine versus peg-interferon alfa 2b long term therapy: results of the 4 year copilot trial. J Hepatol 48 Suppl 2 (2008) S4
19. 3 cirrhosis maintenance trial. J Hepatol 50 Suppl 1 (2009) S22
20. Shiffman M.L., Sterling R.K., Hofmann C., et al. Low-dose peginterferon alfa-2a maintenance therapy reduces portal pressure in patients with advanced fibrosis and cirrhosis. Hepatology 48 Suppl (2008) 1045A
21. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 (2005) 453-471
22. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
23. Sánchez-Tapias J.M., Diago M., Escartín P., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006) 451-460
24. Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694
25. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
26. Kwo P., Lawitz E.J., McCone J., et al. HCV Sprint-1: Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology 48 Suppl 4 (2008) 1027A
27. McHutchison J.G., Shiffman M.L., Terrault N., et al. A phase 2B study of telaprevir with peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon alfa-2a/b and ribavirin therapy: prove 3 interim results. Hepatology 48 Suppl 4 (2008) 431A